Procan® - Children’s Medical Research Institute (CMRI)
Academic institution
Westmead
New South Wales, Australia
ProCan® is a registered trademark and the abbreviated name of The Australian Cancer Research Foundation International Centre for the Proteome of Human Cancer, is an international research project located at Children's Medical Research Institute (CMRI) in Sydney and involves dozens of national and international collaborations. ProCan is a world-first initiative developed by Professors Roger Reddel and Phil Robinson which launched in September 2016.
ProCan is developing a database of information to advance scientific discovery and enhance clinical treatment worldwide by more precisely diagnosing cancers and effectively narrowing down the best type of currently available treatment to target an individual patient's cancer. Scientists at CMRI are analysing tens of thousands of examples of all types of cancer from all over the world to develop a library of information to advance scientific discovery and enhance clinical treatment worldwide.
This database will mean doctors can effectively narrow down the best type of currently available treatment to target a cancer patient’s individual diagnosis, without having to waste time trialling medications that won’t effectively treat the disease.
ProCan is acting in partnership with cancer researchers, clinicians, tumour banks, and technology experts, such as Professor Ruedi Aebersold in Zurich whose 2015 Nature paper acted as the 'proof of concept' for us to undertake, on a much larger scale, the ProCan project.
ProCan is developing a database of information to advance scientific discovery and enhance clinical treatment worldwide by more precisely diagnosing cancers and effectively narrowing down the best type of currently available treatment to target an individual patient's cancer. Scientists at CMRI are analysing tens of thousands of examples of all types of cancer from all over the world to develop a library of information to advance scientific discovery and enhance clinical treatment worldwide.
This database will mean doctors can effectively narrow down the best type of currently available treatment to target a cancer patient’s individual diagnosis, without having to waste time trialling medications that won’t effectively treat the disease.
ProCan is acting in partnership with cancer researchers, clinicians, tumour banks, and technology experts, such as Professor Ruedi Aebersold in Zurich whose 2015 Nature paper acted as the 'proof of concept' for us to undertake, on a much larger scale, the ProCan project.
